AMRN · AMRN Q2 FY2026 earnings call record财报电话会记录

“As you may have noticed in our press release, we're now able to provide an outlook for certain key metrics for full year 2026, reflecting the clarity afforded by our new operating model and the strong partnerships that make up its foundation.”

“As of June 30th, 2026, VASCEPA was commercially available in 22 countries via both our fully partnered international commercial strategy and company-managed U.S.”

“Our accelerating international growth is being driven primarily by our exclusive license and supply agreement with Recordati, which covers 59 countries across Europe, as well as our six other commercial partnerships in the rest of the world that cover regions including Canada, China, Israel, the Middle East, Asia, Australia, and New Zealand.”

“Across this combined global partner network, in-market demand for VASCEPA rose by 59% in cumulative year-over-year volume as of June 30th, compared to the same period last year.”

“In-market demand in Europe for VASCEPA under the Recordati partnership rose by 69% in Q2 2026 from Q2 2025.”

“In its 2025 annual report, Recordati referred to VAZKEPA as a best-in-class treatment option that complements its existing cardiovascular portfolio, is supported by a robust clinical data package, and makes a meaningful impact for cardiovascular patients with residual cardiovascular risk.”

“volumes to remain stable through the end of 2026.”

“approval of VASCEPA for cardiovascular risk reduction, we continue to invest in meaningful scientific research that expands our understanding of cardiovascular risk and reinforces the role of high-dose VASCEPA in contemporary clinical practice.”

“product revenues declined to $32.2 million from $36.5 million in Q2 2025, driven by ongoing pricing pressure in the competitive generic market, partially offset by higher product volumes.”

“Cost of goods sold in Q2 2026 rose 22% to $27.2 million from $22.4 million due to increased product volumes, primarily associated with regaining an exclusive PBM relationship in the U.S.”

“Turning to the balance sheet, we ended the quarter with cash and investments of $314.6 million, up from $303 million at year-end 2025, with no debt and working capital of $439 million.”

“Importantly, we generated $7 million of positive cash flow from operations in the second quarter, our third consecutive quarter of positive cash flow, and we continue to expect positive cash flow for full year 2026.”